Highlights:
-CX 2014 audience recognises the impact of drug-eluting balloons
-No type I or III endoleaks with the Incraft system for EVAR at two years
-Lindsay Machan: Radiation hazards
-Mark S Whiteley: Heat ablation
-Profile: Cliff Shearman
[pdfviewer width=”100%” height=”940px” beta=”true”]https://vascularnews.com/wp-content/uploads/sites/7/2016/02/62-Vascular-News-USA_low-res.pdf[/pdfviewer]
